BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.05
$0.171.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | ||
|---|---|---|---|---|---|
| Net Income | -97.07% | -158.37% | -30.30% | -42.82% | |
| Total Depreciation and Amortization | 273.08% | 248.08% | 248.08% | 3.85% | |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | |
| Total Other Non-Cash Items | 1,328.50% | 2,167.35% | -62.35% | -39.72% | |
| Change in Net Operating Assets | -247.45% | 214.75% | -63.69% | -70.60% | |
| Cash from Operations | -180.90% | -25.23% | -185.63% | -121.08% | |
| Capital Expenditure | -630.00% | -1,172.73% | -1,550.00% | -1,057.14% | |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | |
| Cash Acquisitions | -- | -- | -- | -- | |
| Divestitures | -- | -- | -- | -- | |
| Other Investing Activities | -69.34% | 1,240.86% | 106.52% | 545.47% | |
| Cash from Investing | -69.61% | 1,241.10% | 106.36% | 542.47% | |
| Total Debt Issued | -- | -- | -- | -- | |
| Total Debt Repaid | -- | -- | -- | -- | |
| Issuance of Common Stock | -13.46% | -- | -- | -- | |
| Repurchase of Common Stock | -- | -- | -- | -- | |
| Issuance of Preferred Stock | -- | -- | -88.85% | -- | |
| Repurchase of Preferred Stock | -- | -- | -- | -- | |
| Total Dividends Paid | -- | -- | -- | -- | |
| Other Financing Activities | -- | -- | -- | -- | |
| Cash from Financing | -1,226.92% | -- | -90.50% | -106.08% | |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | |
| Net Change in Cash | -431.54% | 1,991.03% | -86.72% | -2,763.79% | |